Keyphrases
Cell-based
100%
Potentiation
100%
Tumor Lysate
100%
Therapeutic Vaccine
100%
Recombinant interleukin-2
100%
Pulsed DC
83%
Interleukin-2
66%
Immunogenic
66%
Tumor
50%
Dendritic Cells
33%
T Cells
33%
Sarcoma
33%
DC-based Vaccine
33%
Novel Treatments
16%
C57BL
16%
Mouse Model
16%
Immune Response
16%
T Cell Activation
16%
Antitumor Activity
16%
Murine Model
16%
Tumor Cells
16%
Colorectal Cancer
16%
Operative
16%
Immunization
16%
Tumor-specific
16%
Phase III Clinical Trial
16%
B16 Melanoma
16%
Antitumor Effect
16%
Growing Tumor
16%
B6 Mice
16%
Therapeutic Efficacy
16%
Vive
16%
Mouse Tumor Model
16%
Host Specificity
16%
Melanoma
16%
Systemic Administration
16%
Protective Immunity
16%
Vaccine Therapy
16%
Antitumor Immune Response
16%
Autoimmune T Cells
16%
Tumor Antigen
16%
Melanoma Cancer
16%
Advanced Melanoma
16%
Mean Survival Time
16%
Treatment Support
16%
Tumor Challenge
16%
Immunology and Microbiology
Dendritic Cell
100%
Cell Lysate
100%
Recombinant Interleukin 2
100%
Tumor Vaccine
100%
Interleukin 2
66%
T Cell
50%
Immune Response
33%
Cytokine
16%
Mouse Model
16%
C57BL 6 Mouse
16%
Tumor Cell
16%
Cell Function
16%
Antineoplastic Activity
16%
Tumor Antigen
16%
Immunity
16%
Preclinical Study
16%
Survival Time
16%
Vaccine Therapy
16%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
100%
Tumor Vaccine
100%
Recombinant Interleukin 2
100%
Interleukin 2
30%
Melanoma
15%
Connective Tissue Cancer
15%
Combination Therapy
7%
Clinical Trial
7%
Cytokine
7%
C57BL 6 Mouse
7%
Mouse Model
7%
Melanoma B16
7%
Antitumor Activity
7%
Preclinical Study
7%
Survival Time
7%
Tumor Model
7%
Tumor Antigen
7%
Systemic Administration
7%
Colorectal Carcinoma
7%